These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16950005)

  • 1. Chapter 21: Modelling the impact of HPV vaccines on cervical cancer and screening programmes.
    Garnett GP; Kim JJ; French K; Goldie SJ
    Vaccine; 2006 Aug; 24 Suppl 3():S3/178-86. PubMed ID: 16950005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
    Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
    PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus and cervical cancer in Australasia and Oceania: risk-factors, epidemiology and prevention.
    Garland SM; Brotherton JM; Skinner SR; Pitts M; Saville M; Mola G; Jones RW
    Vaccine; 2008 Aug; 26 Suppl 12():M80-8. PubMed ID: 18945417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
    Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
    Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating human papillomavirus vaccination in cervical cancer control programmes.
    Franco EL; Coutlée F; Ferenczy A
    Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of cytology screening and HPV vaccination on the burden of cervical cancer.
    Tay K; Tay SK
    Asia Pac J Clin Oncol; 2011 Jun; 7(2):154-9. PubMed ID: 21585695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.
    Adams M; Jasani B; Fiander A
    Vaccine; 2007 Apr; 25(16):3007-13. PubMed ID: 17292517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural differences among cost-effectiveness models of human papillomavirus vaccines.
    Insinga RP; Dasbach EJ; Elbasha EH
    Expert Rev Vaccines; 2008 Sep; 7(7):895-913. PubMed ID: 18767941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
    Wong G; Howard K; Webster A; Chapman JR; Craig JC
    Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
    Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
    Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for cervical cancer prevention in Asia Pacific.
    Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
    Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N
    Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination against HPV: indications for women and the impact on the cervical screening programme.
    Heideman DA; Snijders PJ; Berkhof J; Verheijen RH; Helmerhorst TJ; Meijer CJ
    BJOG; 2008 Jul; 115(8):938-46. PubMed ID: 18651878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.
    Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY
    Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination.
    Franco EL; Cuzick J; Hildesheim A; de Sanjosé S
    Vaccine; 2006 Aug; 24 Suppl 3():S3/171-7. PubMed ID: 16844268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
    Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
    Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing.
    Schiffman M
    Cancer; 2007 Jun; 111(3):145-53. PubMed ID: 17487850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current and future role of screening in the era of HPV vaccination.
    Myers E; Huh WK; Wright JD; Smith JS
    Gynecol Oncol; 2008 May; 109(2 Suppl):S31-9. PubMed ID: 18482556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficiency of human papillomavirus vaccination--estimates based on Dutch cost effectiveness analyses].
    Westra TA; Daemen T; Postma MJ; Wilschut JC
    Ned Tijdschr Geneeskd; 2009; 153():A356. PubMed ID: 19930733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Implementation of HPV vaccination in Germany].
    Schreckenberger C; Kaufmann AM; Schneider A
    Dtsch Med Wochenschr; 2007 Oct; 132(42):2221-4. PubMed ID: 17926251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.